Drug Profile
Research programme: cannabinoid receptor CB1 antagonists - ACADIA Pharmaceuticals
Latest Information Update: 30 Mar 2012
Price :
$50
*
At a glance
- Originator ACADIA Pharmaceuticals
- Class Small molecules
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cognition disorders; Obesity; Substance-related disorders
Most Recent Events
- 31 Dec 2010 Discontinued - Preclinical for Cognition disorders in USA (PO)
- 31 Dec 2010 Discontinued - Preclinical for Obesity in USA (PO)
- 31 Dec 2010 Discontinued - Preclinical for Substance-related disorders in USA (PO)